References are given to several genomic, proteomic and metabolomic databases in this report and these are relevant to biomarkers. The value of such databases is recognized. Building of reliable biomarker databases and integration of information from the genome programs expands the scientific frontiers on etiology, health risk prediction and prevention of environmental disease. Biomarker validation may be performed in a number of ways: bench-side in traditional labs; web-based electronic resources such as gene ontology; literature databases; and clinical trial. Biomarker databases have potential value for pharmaceutical research and development.
The biomarker database GOBIOM (https://gobiomdb.com/gobiom/), contains >115,000 biomarkers (as of April 2017), including genomic, biochemical, imaging, metabolite, cellular, and other biomarkers, as well as data points from experimental, analytical, clinical, and statistical data with their qualifications under different medical interventions. The database includes information from >200,000 sources including clinical trials, scientific conferences, regulatory approval documents, literature databases, patents, etc. It covers 18 therapeutic areas and 1700 indications. It may be used in biomarker design and validation research. Under an agreement, the FDA uses GOBIOM as part of its Voluntary Exploratory Data Submission Program and in internal research projects. The Prevention of Organ Failure Center (PROOF Center) at the University of British Columbia, Canada, has agreed to use the GOBIOM to assess the commercialization potential of the its studies of biomarker development for heart, lung, and kidney failure.